MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Clinical trials for MINIMALLY INVASIVE LUNG ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MINIMALLY INVASIVE LUNG ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for MINIMALLY INVASIVE LUNG ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a new drug boost lung cancer treatment?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemoradiation helps people with stage III non-small cell lung cancer that can't be surgically removed. It first finds the best dose, then compares the combination to standard treatment alone. About 53 adults particip…
Matched conditions: MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:46 UTC
-
New combo therapy aims to keep early lung cancer from returning
Disease control OngoingThis study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation (SABR) helps keep early-stage non-small cell lung cancer from coming back. About 140 people with stage I-IIA or recurrent lung cancer will be randomly assigned to get radiation alone…
Matched conditions: MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:32 UTC
-
Immunotherapy duo takes on rare tumors in nationwide trial
Disease control OngoingThis study tests two immunotherapy drugs, nivolumab and ipilimumab, in adults with over 50 types of rare cancers. The goal is to see if this drug combination can shrink tumors or stop them from growing. The trial is no longer enrolling new participants, but results will help guid…
Matched conditions: MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:30 UTC
-
New cocktail for inoperable lung cancer shows promise in early trial
Disease control OngoingThis study tested a three-part treatment for people with stage III lung cancer that cannot be removed by surgery. The treatment combined standard chemotherapy (cisplatin and etoposide) with radiation, followed by two additional drugs (docetaxel and bevacizumab) to try to kill mor…
Matched conditions: MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:06 UTC